Table 4 Quality assessment of clinical trials of oral antibiotic therapy in infective endocarditis
From: Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review
|  | Provides case definition for infective endocarditis | Defines eligibility criteria | Provides details of the setting and location of the study | Provides detailed description of the intervention | Details processes for ascertainment and measurement of outcomes | Provides justification for sample size | Establishes an adequate sequence generation | Allocation concealment | Blinding (study drug) | Blinding (outcomes) | Analysis of safety of the intervention | Describes participants’ flow | Addresses incompleted outcome data | Addresses risk of selective reporting | Provides information on accessibility to the study protocol, trial registration and funding for the study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Heldman et al[18] | √ | √ | √ | √ | √ | √ | √ | X | X | X | √ | √ | √ | √ | √ |
Stamboulian et al[19] | √ | √ | √ | √ | X | X | X | X | X | X | X | N.A. | N.A. | N.A. | X |